GET DAILY SIGNALSAstraZeneca (AZN) Stock: Analysts See +13% Upside to $210 Target
Key Takeaways
- The central AZN stock price target of $210 is the arithmetic mean of recent analyst price targets—which cluster around $206 to $208—rounded to a clean level, implying roughly 13% upside from a price near $186.
- Analyst targets span a wide range, from about $158 (a cautious Deutsche Bank view) up to $240 (TD Cowen and Leerink), with Bernstein's London-listed target implying an even higher ADR value.
- The prevailing analyst consensus is Buy or Overweight, built on oncology momentum and a deep, advancing drug pipeline.
- Key supports include 2026 guidance for mid-to-high single-digit revenue growth and low-double-digit core EPS growth, plus a $2 billion oncology partnership with Summit Therapeutics.
- Principal risks are a bearish minority view, drug-pricing and patent-expiry pressures, and the unusually wide spread between the highest and lowest targets.
Analyst Price Targets and Consensus View
AstraZeneca PLC, the British-Swedish pharmaceutical group whose U.S.-listed ADR trades under the ticker AZN, carries a broadly constructive analyst consensus. Across the most widely followed data providers, the average U.S.-listed price target sits between roughly $206 and $208, which rounds to a central target of $210. This is a calculated mean, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The dispersion is unusually wide. At the cautious end, Deutsche Bank holds a target near $158, while HSBC downgraded the shares to Hold. At the bullish end, TD Cowen maintains a $240 target and Leerink Partners $220. Morgan Stanley (Overweight) and J.P. Morgan sit in the $213–$220 zone, Goldman Sachs recently raised its target toward the mid-$230s, and Bernstein's London-listed target implies an ADR value above the rest of the range. The gap between the low and high targets reflects genuine disagreement about the pace of pipeline monetization and the sustainability of premium growth.
Current Market Position and Path Toward the Target
With the stock trading near $186, reaching $210 would require a move of roughly 13%, a modest-to-moderate advance for a large-cap pharmaceutical name. The path hinges less on valuation re-rating and more on continued execution. AstraZeneca reaffirmed 2026 guidance for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates, and third-quarter results beat expectations, with core operating profit and core EPS ahead of consensus.
The company's oncology franchise—led by Tagrisso, Imfinzi, Calquence, and Enhertu—remains the central growth engine, supplemented by cardiovascular, renal, and metabolism products such as Farxiga. Recent positive Phase III readouts and a $2 billion partnership with Summit Therapeutics focused on gastrointestinal cancers reinforce the pipeline narrative that underpins most Buy ratings.
What Could Support a Move Toward the Target
- Oncology momentum: Strong demand across Tagrisso, Imfinzi, Calquence, and Enhertu supports revenue growth above the sector average.
- Guidance and earnings: Reaffirmed 2026 outlook and an earnings beat give analysts a concrete basis for their price forecasts.
- Pipeline catalysts: Positive late-stage results, including tozorakimab in COPD and efzimfotase alfa, expand the addressable market.
- Strategic deals: The Summit Therapeutics oncology partnership adds optionality in a high-growth therapy area.
- Analyst revisions: Several firms have raised targets through late 2026, reflecting a gradually improving earnings outlook.
What Could Prevent the Target From Being Reached
- Bearish minority: Deutsche Bank's cautious stance and HSBC's Hold downgrade show that not all analysts share the bullish view.
- Pricing and patent pressure: U.S. drug-pricing reform and looming loss of exclusivity on key products could compress long-term growth.
- Execution risk: A high valuation multiple leaves limited room for disappointment if trial readouts or launch trajectories underwhelm.
- Sector rotation: A shift away from defensive healthcare names during a risk-on market could limit near-term upside.
Technical Levels and Market Structure
The stock traded above $200 earlier in 2026 before pulling back toward the mid-$180s, making the $200 round-number level a meaningful psychological and resistance reference point on any recovery. A sustained move toward $210 would first require reclaiming that area. Conversely, the recent pullback lows near the low-to-mid $180s represent the nearest support zone to watch if selling pressure resumes.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms apply different assumptions and timelines. Investors should monitor quarterly earnings and guidance updates, analyst target revisions, regulatory and trial milestones across the oncology and respiratory pipelines, U.S. and European drug-pricing policy, and the performance of the broad healthcare sector. None of these offers a definitive timing signal, but together they shape the realistic path toward the $210 target. From what I see, this is important because it highlights how execution will ultimately determine whether the target is reached.
Exploring AI Daily Buy/Sell Signals for Additional Context
For traders seeking a data-driven complement to fundamental research, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Traders interested in a systematic, technology-enabled view of the market can explore these signals as part of a broader decision-making process.
Final Assessment
The $210 central target for AstraZeneca reflects a modest, pipeline-supported upside of about 13% from current levels. The bullish case rests on oncology leadership, reaffirmed guidance, and a series of positive clinical and strategic developments, while the principal obstacles are a persistent bearish minority, pricing and patent risks, and a wide gap between the highest and lowest analyst targets. Because the range is so broad—roughly $158 to $240—the average should be read as a midpoint of genuinely divergent views rather than a forecast. Whether the stock reaches $210 will depend on sustained execution and upcoming catalysts, not on the target itself. I’m watching this closely as new data emerges.
Using Tickeron AI Tools in My Research
In my own work, I often turn to Tickeron’s suite of AI tools to cross-check analyst views and spot patterns in real time. The AI Daily Buy/Sell Signals have been particularly useful for layering quantitative signals over the fundamental story, helping me stay objective when evaluating names like AZN amid shifting market conditions. It’s a practical way to add discipline without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AZN turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 27 of 42 cases over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 50 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.749) is normal, around the industry mean (-1.421). P/E Ratio (27.660) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement